1 Chemical/technical risk analysis of a new multi-directional nebulizer (MDN) and its clinical implementation for the safe administration of 2 Pressurized Intraperitoneal Aerosol Chemotherapy (MDN-PIPAC) 3 4 5 Short title: MDN-PIPAC is feasible and safe 6 7 8 Fabian Kockelmann, MD¹, Daniel Göhler, Dipl.-Ing.^{2,3}, Sarah Barbey⁴, Amayu Wakoya 9 Gena, M. Arch⁵, Hayder Alsaad, Dr.-Ing.⁵, Conrad Voelker, Prof, Dr.-Ing.⁵, Jürgen Zieren, 10 Prof, MD¹, Mehdi Ouaissi, Prof. MD, PhD^{6,7}, Urs Giger-Pabst, Prof, MD^{6,8} 11 12 ¹ Department of Surgery, Klinikum Dortmund, Hospital of the Witten/Herdecke University, 13 Germany 14 ² Topas GmbH, Dresden, Germany 15 ³ Research Group Mechanical Process Engineering, Institute of Process Engineering and 16 17 Environmental Technology, Technische Universität Dresden, Dresden, Germany ⁴ Plateforme Pixanim, INRAE PRC, 37380, Nouzilly, France 18 ⁵ Department of Building Physics, Bauhaus-University Weimar, Weimar, Germany 19 ⁶ EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France 20 21 ⁷ Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, France 22 ⁸ Fliedner Fachhochschule, University of Applied Sciences, Düsseldorf, Germany 23 24 25 26 27 28 Correspondence: 29 Fabian Kockelmann, MD 30 Department of Surgery Klinikum Dortmund 31 Hospital of the Witten/Herdecke University, Germany 32 Tel: +49 0231 953-21430 33 34 Fax: +49 0231 953-21108 35 Email: fabian.kockelmann@uni-wh.de

$Kockelmann\ et\ al.-V4_AW_HA\ (1)$

ABBREVIATIONS

37	AET	Analytical Evaluation Threshold (ISO 10993-18 (2020)
38	BSA	Body Surface Area calculated according to DuBois
39	CE	Conformité Européenne
40	DGAV	Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
41	ECOG	Eastern Cooperative Oncology Group
42	FDA	U.S. Food and Drug Administration
43	GC-MS	Gas Chromatography coupled with Mass Spectrometry
44	HSGC-MS	Head-space Gas Chromatography coupled with Mass Spectrometry
45	IC	Ion Chromatography
46	ICP-OES	Inductively Coupled Plasma Atomic Emission Spectrometry
47	LC-MS	Liquid phase chromatography □ coupled to a Mass Spectrometer
48 49	MDN	Multi-Directional Nebulizer (QuattroJet TM , REGER Medizintechnik GmbH, Villigendorf, Germany)
50	PCI	Peritoneal Carcinomatosis Index according to Sugarbaker
51	PIPAC	Pressurized IntraPeritoneal Aerosol Chemotherapy
52	PSM	Peritoneal Surface Malignancies
53	RIPAC	Rotational intraperitoneal aerosol chemotherapy
54	SDN	Single-direction nebulizer
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		

AUTHOR CONTRIBUTIONS

- 66 Fabian Kockelmann and Urs Giger-Pabst: study design, coordination of the study, data
- 67 acquisition, data interpretation, logistics, drafting of the manuscript, and critical revision of
- the manuscript

65

77

78

84

85

93

94

101

- 69 Amayu Wakoya Gena, Hayder Alsaad and Conrad Voelker: schlieren experiments, drafting of
- 70 the manuscript, and critical revision of the manuscript
- 71 Daniel Göhler and Mehdi Ouaissi: drafting of the manuscript and intellectual and scientific
- 72 contributions depending on their field of expertise
- 73 Sarah Barbey: study protocol, coordination of animal experiments, and perioperative
- 74 management of animals
- Jürgen Zieren: study design, PIPAC procedures, data acquisition, data interpretation, logistics,
- drafting of the manuscript, and critical revision of the manuscript

DISCLOSURE

- All authors have no conflicts of interest or financial ties to disclose. The animal experiments
- 80 were funded by the Association Tourangelle de recherche en oncologie du val de Loire (AT-
- 81 ROVL). All data produced in the present study are available upon reasonable request to the
- authors. The MDNs for the ex- and in-vivo animal experiments were provided from REGER
- 83 Medizintechnik GmbH, Villigendorf, Germany)

ACKNOWLEDGEMENTS

- We are thankful to Aesculap Akademie GmbH, Bochum, Germany for providing the technical
- 87 equipment to simulate laparoscopic surgery. Especially to Mrs. Anna-Maria Krug, Training
- 88 Manager at Aesculap Akademie GmbH, Bochum, Germany for her important help. We also
- 89 thank Mr. Mohsen Faraji and Mr. Burak Kabakci, Technomedics GmbH Illertissen, Germany
- 90 for providing technical and logistical support for the schlieren experiments in Weimar,
- 91 Germany. The schlieren flow visualizations were supported by the German Research
- 92 Foundation (DFG), Grant No. 444059583.

MINI ABSTRACT

- 95 Toxicological analyses confirm that doxorubicin, cisplatin, and oxaliplatin nebulized with the
- 96 MDN do not release leachables that pose a toxicological risk to patients. Through technical
- 97 risk analysis and PIPAC simulations, a safety concept for the administration of MDN-PIPAC
- 98 was established. No technical/medical intraoperative adverse events were observed. The
- 99 perioperative course was comparable to that of the conventional axial single-direction
- nebulizer (SDN) PIPAC.

ABSTRACT

102

- 103 Background/Aim: To test the chemoresistance of a multi-directional nebulizer (MDN) and to
- establish and implement a perioperative clinical safety concept for its clinical use to deliver
- pressurised intraperitoneal aerosol chemotherapy (MDN-PIPAC).
- 106 Study design: Ex-vivo nebulization of cytostatic drugs with the MDN device to assess
- 107 chemoresistance/toxicological risks. Establishment of a perioperative safety concept for the
- 108 clinical administration of MDN-PIPAC by ex- and in-vivo porcine simulation studies.
- 109 Unicentric case series of 30 MDN-PIPACs in 21 patients with peritoneal surface malignancies
- 110 (PSM). Endpoints were intraoperative adverse events and perioperative complications
- 111 (Clavien-Dindo).
- 112 **Results:** Toxicological studies/risk assessment confirm the safety of administering PIPAC
- with the MDN. The horizontal nozzles must protrude at least 7 mm beyond the most distal
- end of the trocar tip and lateral tilting should be prevented by fixation of the device in a
- single-arm holder. A total of 21 patients (male/female ratio: 2:1) with a mean age of 62
- 116 (range: 38-86) years underwent 30 consecutive MDN-PIPACs for peritoneal surface
- malignancies of different origin. ECOG 0 and 1 were seen in five and 16 patients,
- respectively. Thirteen, seven, and one patient underwent one, two, and three MDN-PIPACs,
- 119 respectively. Two patients received only one cycle of MDN-PIPAC because they were
- considered candidates for cytoreductive surgery and heated intraperitoneal chemotherapy.
- 121 There were no intraoperative technical/medical problems observed. Four patients suffered
- from postoperative grade I complications.
- 123 Conclusions: Compounds leached during chemotherapy nebulization with the MDN are
- toxicologically safe. MDN-PIPAC administrations are safe and the postoperative course is
- comparable to that of the conventional PIPAC nebulizer.

127 **KEYWORDS**

- 128 PIPAC, multi-directional nebulizer (MDN), MDN-PIPAC, chemical compatibility,
- toxicological risk analysis, CT-peritoneography, schlieren imaging, clinical safety, clinical
- 130 feasibility

126

1.0 INTRODUCTION

- For more than a decade, pressurised intraperitoneal aerosol chemotherapy (PIPAC) has been
- used for the treatment of peritoneal surface malignancies (PSM). Clinical results are
- encouraging, but data from prospective, randomized trials clearly demonstrating the efficacy
- of this treatment are still lacking [1, 2]. A common feature of all previously available
- nebulizers for PIPAC therapy is that they all have only one nebulizer unit (axial single-
- direction nebulizer (SDN)), which ejects the chemotherapeutic droplets in an axial direction.
- The majority (97.5 % of the volume) of the nebulized chemotherapy impacts the peritoneum
- directly, which is located below the nebulizer orifice [3]. It has also been suggested that the
- locally high drug deposition that occurs when using a SDN results in potential local toxicity
- that could lead to an increase in perioperative complications, particularly when additional
- surgical procedures such as complex adhesiolysis or bowel resection are performed at the
- same time as PIPAC [4 6]. However, more recent clinical data appear to relativise such
- assumptions [7].

132

164

165

- However, the PIPAC nebulizer technology has been further developed to optimize the spatial
- 147 distribution of the drug. A new and innovative concept is multi-directional drug
- 148 aerosolization. Recent data obtained with a multi-directional drug nebulizer prototype
- 149 reported an improved spatial drug distribution pattern in an ex-vivo PIPAC model compared
- to standard SDN technology [8].
- 151 A first multi-directional nebulizer (MDN) for the clinical off-label application of PIPAC
- 152 (MDN-PIPAC) is now commercially available. In addition to the conventional axial nozzle,
- three additional horizontal nozzles are integrated into the nebulizer head at 120° intervals.
- This nozzle configuration enables nebulization of the chemotherapy over a spray angle of
- almost 240° compared to 77° with a SDN [9]. Since there are still no documented preclinical
- or clinical applications with this device worldwide, we decided to conduct further extensive
- preclinical studies before the first clinical MDN-PIPAC applications.
- Therefore, the objectives of this study were (i) to investigate a potential toxicological risk
- from substances leaking from the device when used in combination with cytotoxic drugs, and
- (ii) to develop an intraoperative safety concept for the administration of MDN-PIPAC using
- an ex-vivo PIPAC model, schlieren imaging, and in-vivo large animal CT peritoneography,
- and iii) to analyse a consecutive case series of 30 MDN-PIPACs to evaluate perioperative
- safety and feasibility in patients with peritoneal surface malignancies (PSM).

2.0 MATERIAL & METHODS

- 166 2.1 Research sites and institutes: Nebulization for cytostatic drug
- compatibility/toxicology studies of the MDN and the in-vivo animal experiments were carried
- out at the French National Research Institute for Agriculture, Food and Environment
- 169 (INRAE), Centre Val de Loire Nouzilly, France. Schlieren imaging was performed at the
- Bauhaus-University Weimar, Weimar, Germany. Chemical characterisation and toxicological

- evaluation were conducted by RESCOLL, Pessac, France, and TentaConsult Pharma & Med
- 172 GmbH, Münster, Germany, respectively.
- 173 2.2 MDN chemotherapy compatibility study: Doxorubicin, cisplatin, and oxaliplatin were
- purchased from Hexal AG, Holzkirchen, Germany, Accord Healthcare B.V. Utrecht, the
- Netherlands, and Medac GmbH, Wedel, Germany. Drug doses (doxorubicin 6 mg, cisplatin
- 176 30 mg, and oxaliplatin 120 mg per m² of body surface area (BSA)) were studied according to
- data from phase I safety studies and clinical use [10 12]. A patient with a height of 1.90 m
- and a weight of 100 kg was assumed. The BSA was calculated according to the DuBois
- formula [13]. Glucose 5% and NaCl 0.9% were purchased from B. Braun, Melsungen,
- 180 Germany. Oxaliplatin was diluted with glucose 5% and doxorubicin and cisplatin with NaCl
- 181 0.9% to a total of 50 ml and 150 ml, respectively. The same solutions were used as blank
- controls. Blank control solutions were immediately filled into sterile glass bottles (ref. #
- FRAA-250-60, Labbox GmbH, Düsseldorf, Germany) and stored protected from light at 4°C.
- The chemotherapy solutions for nebulization experiments were filled into syringes (ELS 200
- 185 ml (S), MEDTRON AG, Saarbrücken, Germany), the syringe instated into the high-pressure
- injector head (Accutron® HP-D Vision, MEDTRON AG, Saarbrücken, Germany), vented,
- and then connected to the high-pressure line of the MDN (QuattroJetTM, REGER
- Medizintechnik GmbH, Villigendorf, Germany). The shaft of the MDN was wrapped with
- sterile surgical compress proximal to the head of the nebulizer and then positioned vertically
- in a tight and stable position in the neck of a sterile 250 ml glass bottle (ref. # FRAA-250-60,
- 191 Labbox GmbH, Düsseldorf, Germany). Nebulization could take place unhindered with the
- nebulizer head in the body of the bottle at a flow rate of 1.5 ml/s with an upper pressure limit
- of 300 psi. Nebulization was undertaken under a vertical laminar air flow bench. Doxorubicin
- and Cisplatin were nebulized one after the other but into the sample bottle. All experiments
- 195 were performed in triplicates. The sample and blank control solution bottles were sealed
- airtight immediately after the experiments and stored protected from light at 4°C. The samples
- were transported to the laboratory for further processing by courier within 4 hours while
- 198 refrigeration was maintained.
- 199 2.3 Chemical characterisation and toxicological risk assessment: MDN device
- 200 (QuattroJetTM, REGER Medizintechnik GmbH, Villigendorf, Germany) and chemical
- 201 characterisation according to the ISO 10993-18:2020 [14]. Head-Space Gas Chromatography
- 202 coupled with Mass Spectrometry (HSGC-MS) was used for detecting volatile organic
- 203 compounds, Gas Chromatography coupled with Mass Spectrometry (GC-MS) for detecting
- 204 semi-volatile organic compounds, Liquid Phase Chromatography □ coupled to a Mass
- 205 Spectrometer (LC-MS) for detecting non-volatile organic compounds, Inductively Coupled
- 206 Plasma Atomic Emission Spectrometry (ICP-OES) for quantifying the inorganic elements,
- and Ion Chromatography (IC) for quantifying the ions. The Analytical Evaluation Threshold
- 208 (AET) was applied. The AET defines the threshold below which leachable or extractable
- substances cannot be identified or quantified and therefore it can be assumed without further
- evaluation that such a substance does not pose a toxicological risk.
- The parameters used for the toxicological risk assessment were set to consider the worst case.
- 212 Three consecutive MDN-PIPAC administrations were assumed with no time interval in

- between (instead of a treatment interval of four to six weeks between each PIPAC cycle). In
- 214 addition, the exposure of children with a body weight of 10 kg was calculated with the
- amount used for the treatment of an adult. The toxicological risk associated with leachables
- was assessed by collecting data and identifying critical health endpoints through literature
- searches and toxicological risk assessment from PubChem (HSDB), PubMed, ChemIDplus,
- 218 ECHA databases, and various other online sources and databases (e.g., FDA.gov) in
- 219 accordance with ISO 10993-17:2023 [15].

220 2.4 Preclinical assessment of the MDN-PIPAC safety checklist and schlieren imaging:

- As a first step, a team of two surgeons and one PIPAC nurse analysed whether the use of the
- 222 MDN (QuattroJetTM, REGER Medizintechnik GmbH, Villigendorf, Germany) could result in
- 223 additional intraoperative risks or hazards for healthcare personnel. Potential risks were
- 224 assessed for clinical relevance. Appropriate safety measures were then developed and
- integrated into our existing intraoperative PIPAC safety checklist [16]. In a second step, using
- 226 this adapted intraoperative PIPAC safety checklist, the team repeatedly simulated MDN-
- 227 PIPAC applications in the operating room using NaCl 0.9% (B. Braun, Melsungen, Germany)
- on an established ex-vivo PIPAC model [17] to test the coherence of the adapted
- 229 intraoperative PIPAC safety measures and the safety checklist.
- 230 In addition, the schlieren imaging system of the Bauhaus-University Weimar (Figure 1) was
- used to investigate the potential for chemotherapy aerosol/CO₂ backflow through the trocar
- valve system into the operating theatre environment during MDN-PIPAC. A worst-case
- 233 scenario was simulated in which the head of the MDN is misplaced in the trocar shaft,
- 234 resulting in nebulization in the trocar sleeve. Schlieren imaging is a flow visualization
- 235 technique that allows for visualizing density gradients in fluids by capitalizing on the
- refraction of light when entering a medium of different density.
- The utilized schlieren system uses a single concave spherical mirror, where the light beams
- from the source and the returning light rays from the mirror align coincidently, forming an on-
- 239 axis single-mirror coincident schlieren system [18 20]. The system consists of five optical
- 240 elements: concave spherical mirror (1 m in diameter), light source (light-emitting diode
- 241 (LED) including condenser lens and pinhole), beam splitter, schlieren cut-off, and digital
- camera (Canon EOS 5DS R, with 50.6 megapixels image size and a 135 mm focal-length
- lens). The schlieren mirror has a surface accuracy of $\lambda/9.5$, where λ represents the wavelength
- of HeNe laser light. This high level of accuracy makes it highly sensitive, enabling the
- visualization of very small density gradients in fluids. In this study, the density gradient
- 246 results from differences between the leaking CO₂ and the surrounding air. To enhance
- visualization, the CO₂ was heated using an insufflator (Figure 2), creating a sufficiently large
- density gradient for schlieren imaging. The system's ability to visualize this density gradient
- 249 was also tested prior to the investigation (Figure 5A). Throughout the investigations, the
- camera's video imaging was set at 50 frames per second.
- 251 The schlieren flow visualizations investigated possible CO₂/aerosol backflow scenarios during
- 252 clinically relevant MDN-PIPAC scenarios in an ex-vivo PIPAC model with three litre
- volume, MDN in central, vertical position, fixed on a stand in a 12 mm balloon trocar (Kii
- Sleeve with advanced fixation, Applied Medical, California, USA) with lateral nebulizer

255 nozzles that protrude 7 mm beyond the distal end of the trocar shaft. Stable capnoperitoneum

of 12 or 20 mmHg was maintained throughout the whole experiments (Insufflator Flow 50, B.

- 257 Braun SE, Melsungen, Germany). Injection of 50- and 150-ml distilled water at 1.5 ml
- 258 flow/min (SinoPower-D, Sino Medical-Device Technology Co., Ltd, Shenzhen, China).
- Worst-case scenario simulation at 20 mmHg capnoperitoneum, flow rate 1.5 ml/min with
- 260 incorrect positioning of the MDN head in the distal trocar shaft, so that nebulization occurred
- in the trocar shaft. During the flow visualizations, the ex-vivo PIPAC model was placed in
- 262 front of the schlieren mirror (Figure 2).

283

284285

- 263 2.5 In-vivo animal MDN-PIPAC and CT-peritoneography: Domestic pigs were handled 264 and cared for according to all relevant guidelines by authorised investigators. The study (file # 265 40583) was approved by the French Ministry of Higher Education and Research (Ministère de 266 l'enseignement supérieur et de la recherche). A total of three male animals weighing from 47 267 to 42 kg were used. Anaesthesia was induced by intramuscular injection of ketamine 20 268 mg/kg, xylazine 2 mg/kg, and a subcutaneous injection of atropine 0.02 mg/kg, and then 269 completed by endotracheal intubation. The animals were maintained under anaesthesia by 270 isoflurane 3%, intravenous sufentanil, and cisatracurium. The animals were fixed in a supine 271 position in the CT-scanner (SOMATOM Definition AS 128, Siemens, Germany) to deliver 272 HP/HD PIPAC described previously [12]. The MDN was placed at the centre of the abdomen 273 in a perpendicular position so that the horizontal nozzle openings protruded approx. 7 mm 274 beyond the end of the 12-mm trocar (Kii balloon blunt-tip access system, Applied Medical, 275 California, USA). The orientation of these horizontal nozzle openings was chosen so that one 276 nozzle was directed into the right and left upper abdomen and the third nozzle into the small 277 pelvis. Another 5-mm trocar was inserted into the abdominal cavity to monitor the position of 278 the nozzle head with a 5 mm camera and the nebulization process. CT-peritoneography was 279 performed using a modified technique previously described in [21]. For this purpose, 100 ml Imeron® 300 (Bracco Imaging GmbH, Konstanz, Germany) was diluted in 900 ml NaCl 0.9% 280 281 (B Braun, Melsungen, Germany) in a ratio of 1:10. 150 ml of this solution was then 282 administered for HP/HP-PIPAC CT-peritoneography at a flow rate of 1.5 ml/s (Accutron CT-
- 286 2.6 Patients' selection criteria for MDN-PIPAC: The clinical study was performed in 287 line with the guidelines of the Declaration of Helsinki at the Department of Surgery, Klinikum 288 Dortmund, University Hospital of the University Witten/Herdecke, Germany. All patients 289 gave oral and written informed consent. The approval of the Ethics Committee of the Medical 290 Faculty of the University of Münster and the Medical Association Westphalia-Lippe in 291 Germany (file # 2021-360-f-s) was obtained. All patients had histologically confirmed 292 primary or metastatic peritoneal surface malignancies (PSM). Patients were selected by a 293 multidisciplinary tumor board accredited by the German Society for General and Visceral 294 Surgery (DGAV). All procedures were performed as previously described in detail in [10, 12] 295 and were performed by one of the authors (J. Z., senior surgeon). The time interval between 296 cycles was between four to six weeks. Systemic chemotherapy was discontinued one week 297 prior and after MDN-PIPAC. Patients were informed that PIPAC treatment was not provided

D Vision, MEDTRON AG, Saarbrücken, Germany). CT-peritoneography was performed immediately at the end of the HP/HD-PIPAC. After CT acquisition, the animals were

immediately euthanized by intravenous injection of phenobarbital.

within the framework of evidence-based therapy guidelines. All patients gave their oral and 298 written consent. Oxaliplatin at a dose of 120.0 mg/m² body surface area (BSA) diluted in a 299 total of 150 ml glucose 5% was administered in case of PSM of colorectal and appendiceal 300 primary tumours. For all other tumour entities, doxorubicin 6.0 mg/m² BSA diluted in 50 ml 301 NaCl 0.9% followed by cisplatin 30.0 mg/m² BSA diluted in 150 ml NaCl 0.9% was 302 administered [10 - 12]. According to the manufacturer's instructions, the MDN was operated 303 304 at a liquid fluid volume flow of 1.5 ml/s with an upper pressure limit of 300 psi. Access to the 305 peritoneal cavity was always obtained via an infraumbilical open Hasson approach. Before 306 starting the drug nebulization, the capnoperitoneal pressure was increased from 12 to 20 307 mmHg and then kept constant for 30 minutes.

2.7 Perioperative short-term outcome and data acquisition: Retrospective data acquisition of a consecutive case series of 30 delivered MDN-PIPACs. The entire staging laparoscopy, including documentation of the Sugarbaker PCI score, the amount of ascites and the quality of chemotherapy nebulization, is monitored by video according to our standards for intraoperative documentation. All data are stored electronically in the patient's record. Data acquisition and database management are carried out by the co-author J. Z. as part of the required quality assurance as a certified centre of the DGAV. Perioperative adverse events are graded according to the Clavien-Dindo Classification [22, 23]. Data are expressed as absolute numbers whereas continuous data are expressed as are expressed as median values followed by the range in parentheses, i.e. median (range).

3.0 RESULTS

308

309

310

311

312

313

314

315

316

317

318

- 320 3.1 Chemical characterisation and toxicological risk assessment: The results of the
- 321 chemical analyses of nebulized chemotherapy solutions are summarized in Table 1.
- 322 The independent systematic toxicological risk assessment based on the assumption of three
- 323 consecutive PIPAC sessions on the same day in a child with a body weight of 10 kg revealed
- 324 no toxicological risk for the few compounds detected after nebulization.
- 325 3.2 Preclinical technical, safety checklist and surgical approach assessment for MDN-
- 326 *PIPAC*: The following three relevant sub-areas were defined and perioperative measures were
- 327 implemented:
- 328 Operational parameters: According to previous research data and the manufacturer's 329 specifications, the MDN is operated best with a pressure of 150-250 psi with an upper 330 safety limit pressure of 300 psi. In practice, this pressure operating window 331 corresponds to the liquid volume flow rate of 1.2 ml/s-1.6 ml/s. [2]. Accordingly, 332 these operating parameters were stored in the high-pressure injector as a separate MDN-PIPAC working programme. As there are no other differences in handling and 333 334 technical operation compared to the conventional nebulizer used, no additional 335 measures were necessary.
- 336 3.2.2 Construction & Design: Due to the three horizontal nozzles, there is a potential risk of drug nebulization in the trocar if the horizontal nozzles are not placed sufficiently

338339

340

341342

343

344

345346

347

348

349

350

351

352

353

354

355356

357

358 359

360

361

362

363

364

365366

367

368

369

370

371

372

373374

375

376

377

378379

380

beyond the distal end of the trocar into the abdominal cavity. In the worst case, retrograde leakage of chemotherapy through the trocar valve into the operating theatre could occur and harm healthcare workers. To avoid this, the correct positioning of the nebulizer head in the trocar has been added to our standard safety checklist. The four-eye principle is used to check that the horizontal nozzles extend beyond the most distal point of the trocar. It should be noted that most trocars are bevelled at an angle of approximately 15°. The most distal end of the trocar is therefore used as the reference point (Figure 3A).

- 3.2.3 Surgical approach: To optimize spatial aerosol distribution during MDN-PIPAC, the spraying distance between the nozzle orifice and the peritoneum should be as large as possible [2, 7]. Periumbilical, perpendicular placement of the MDN is therefore ideal, if surgically possible (Figure 4A). Additionally, we decided to orientate the MDN in a way that one horizontal spray jet pointed to the right upper, a second to the left upper abdominal quadrant, and the third towards the small pelvis (Figure 4B). In addition, we decided to routinely fix the nebulizer intraoperatively in a single-arm holder (M-TRAC, Braun, Melsungen, Germany) to further prevent tilting and axial sliding into the trocar. The central periumbilical perpendicular MDN position as well as the orientation of the horizontal nozzle orifices were integrated into our intraoperative safety checklist.
- 3.3 Ex-vivo MDN-PIPAC simulation and schlieren imaging: As the distal end of the trocar is angled, special care must be taken to ensure that the distal end of the trocar is visible intraoperatively so as not to interfere with the nebulization of the horizontal nozzles. The correct position of the MDN head has therefore been included as a separate item in our extended safety checklist. The openings of the horizontal nozzles must extend at least 7 mm beyond the distal end of the trocar to avoid interference during nebulization (Figure 3A). In addition, the vertical position of the MDN in the 10/12-mm trocar was found to cause the MDN to tend to slide inward in the trocar without additional fixation. To avoid MDN slippage into the trocar, the device is placed on the trocar head with a rubber ring (sterile, reusable trocar seal) previously pulled over the shaft of the nebulizer in such a way that the rubber ring fits tightly on the trocar head and prevents the nebuliser from slipping inside the trocar (Figure 3B). To further stabilize the position of the MDN, using a single-arm holder turned out to be essential and was therefore also included in our safety checklist. Mispositioning the MDN head with the horizontal nozzles nebulizing in the trocar shaft could cause aerosol leakage into the environment. However, multiple simulations of such a scenario showed no macroscopic detectable retrograde aerosol leakage into the environment. The further schlieren visualisations also showed no leakage of CO₂/aerosol into the environment in any of the scenarios investigated. Even with unfavourable positioning of the MDN head with nebulization in the distal trocar shaft, there was no evidence of even a slight retrograde flow through the trocar valve. Figure 5B shows a representative schlieren image.
- 3.4 In-vivo pig MDN-PIPAC CT-peritoneography: The CT-peritoneographies of the three pigs could be performed without perioperative complications. The animals showed no cardiorespiratory problems due to the capnoperitoneal pressure of 20 mmHg. Our previously

- 381 prepared MDN-PIPAC safety checklist was implemented without any problems. The
- 382 subsequent CT-peritoneographies showed an excellent distribution pattern of the administered
- 383 contrast agent aerosol. However, no contrast agent was visible in the ventral portions of the
- abdominal cavity. Figure 6 depicts representative images of pig N° 1.
- 385 3.5 Clinical baseline characteristics: A total of 21 patients (male/female ratio: 2:1) with a
- mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs. ECOG 0 and 1
- were seen in five and 16 patients, respectively. Patients had PSM of the upper gastrointestinal
- tract (n=6), ovarian cancer (n=4), colorectal cancer (n=3), hepato-pancreatico-biliary tract
- 389 (n=3), malignant epithelioid peritoneal mesothelioma (n=2), and other (n=3). Eleven patients
- 390 had metachronous PSM. Prior to MDN-PIPAC, seventeen patients had undergone primary
- 391 tumor resection. The median number of patients had 2 (range: 1-5) lines of systemic
- 392 chemotherapy before undergoing MDN-PIPAC. Seven patients had previously undergone a
- median of 2 (range: 1-4) PIPACs with the conventional PIPAC nebulizer in our institutions.
- The patients' preoperative baseline data are listed in Table 2.
- 395 3.6 MDN-PIPAC procedure details, morbidity, and mortality: Abdominal access was
- achieved in all patients. Thirteen, seven, and one patient underwent one, two, and three MDN-
- 397 PIPACs, respectively. Two patients received only one cycle of MDN-PIPAC because they
- 398 were considered candidates for cytoreductive surgery (CRS) and heated intraperitoneal
- 399 chemotherapy (HIPEC) at the time of staging laparoscopy for MDN-PIPAC.
- 400 The median Sugarbaker PCI score and ascites at the first MDN-PIPAC were 25 (1-35) and
- 401 200 ml (0-800 ml), respectively. The overall mean (range) operative time was 52.3 (48-78)
- 402 minutes. The gradual pressure build-up and the subsequent exposure phase of 30 minutes at a
- capnoperitoneal pressure of 20 mmHg were well tolerated. No patient showed signs of cardio-
- 404 respiratory impairment from the procedure. No intraoperative surgical or technical problems
- 405 occurred.

414

415

- 406 In total, four patients suffered grade I (Dindo-Clavien) complications after a total of 30 MDN-
- 407 PIPACs (4/30). Three patients experienced persistent nausea and vomiting postoperatively,
- 408 requiring prolonged intravenous rehydration and antiemetic therapy (without gastric tube) for
- 409 48 hours postoperatively. Another patient complained of abdominal pain, which could also be
- 410 managed after extending intravenous analgesic therapy. No complications grade II-V were
- observed. The German health system requires a minimum hospitalization of 3 days for PIPAC
- 412 application in order to be fully reimbursed by the health insurance companies. All patients
- were discharged on the third postoperative day at home.

4.0 DISCUSSION

- 416 For more than a decade, a PIPAC nebulizer has been available for off-label clinical use. This
- 417 technology, with an axially mounted nebulizer unit, has become the standard PIPAC device.
- 418 Due to its design and performance characteristics, the distribution pattern of the atomized
- chemotherapy is not homogeneous. Below the opening of the nebulizer unit, approximately

420 421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437438

439

440

441442

443

444

445

446 447

448

449450

451 452

453

454

455

456

457

458

459

460

461

462

97% by volume is deposited directly onto the underlying peritoneum by inertial impaction [4, 24 - 27]. Recently, other PIPAC nebulizers have become available on the market. However, all nebulizers are based on the same/similar design as the standard technology. Therefore, the problem of local chemotherapy accumulation and inhomogeneous drug distribution pattern in the peritoneal cavity remains unresolved [2], which may affect the oncological efficacy of PIPAC [28]. Therefore, the optimal position of the standard PIPAC nozzle has been investigated in recent years in order to optimize the spatial distribution of chemotherapy [16, 29, 30]. More recently, new experimental PIPAC nozzle technologies have been developed. Rotational intraperitoneal pressure aerosol chemotherapy (RIPAC) uses a modified nebulizer technology similar to the standard PIPAC nebulizer. However, to optimize drug distribution, the nozzle rotates 30° around its vertical axis in the abdominal cavity. In-vivo large animal data indicate that RIPAC leads to a significantly more homogeneous distribution pattern and higher penetration depths of doxorubicin into the tissue compared to the standard PIPAC [31, 32]. Another experimental approach is the use of a preclinical multi-directional nebulizer (MDN). Braet et al. [33] observed in an ex-vivo PIPAC model that the use of their experimental MDN prototype improved the spatial drug distribution of nebulized nanoparticles compared to an SDN. Based on these experimental data, it seems obvious that PIPAC nozzles, which optimize drug distribution, could also be promising in clinical application. For some time now, a CE Class IIa certified MDN has been available for off-label clinical use for MDN-PIPAC [2]. We carried out extensive preclinical testing before introducing this new device into our daily practice. After the premature discontinuation of a French prospective, randomized phase II study (PIPAC EstoK 01) (https://clinicaltrials.gov/study/NCT04065139) [35], it was vividly discussed whether toxic substances could arise during the application of PIPAC due to the interaction of the chemotherapy solution with the PIPAC nebulizer/syringe/tube system. Therefore, independent toxicological investigations were performed as a first step. For the worst-case scenario with the highest chemotherapy doses, the toxicological investigations showed that no relevant toxicologically questionable substances were observed. The risk assessment was further based on the assumption that three PIPACs are administered consecutively on one day to a patient with a body weight of 10 kg. Even this extreme scenario did not reveal any cumulative toxicological risk for patients. Furthermore, these data indicate that the MDN device could also be used in children with a body weight > 10 kg. It is important to emphasize that our toxicological data are only valid for this type of nozzle. According to our current knowledge, there is no data available for other types of nebulizers. Our previous and present technical analysis with PIPAC surgeons and scrub nurses in our department showed that the handling of the MDN differs only slightly from that of the standard nebulizer [2]. The MDN unit requires a higher flow rate which can be programmed into the high-pressure injector. However, a major difference is the three additional nozzles built horizontally into the MDN head. Repetitive ex-vivo simulations have shown that the correct mounting of the nozzle head is crucial. The lateral openings of the nebulizers must protrude at least 7 mm beyond the distal end of the trocar for correct atomization.

incorrect positioning of the MDN head in the trocar shaft could result in a possible aerosol

During the technical risk assessment, concerns were expressed within the PIPAC team that

backflow via the trocar valve into the operating theatre and thus pose a significant risk to

- 464 healthcare staff. As initial simulations with the ex-vivo PIPAC model did not confirm these 465 fears; we carried out additional schlieren imaging experiments. All of them confirm that even when the MDN head is incorrectly positioned, no CO₂ is released retrogradely into the 466 467 environment. Therefore, no backflow of aerosol is assumed based on the CO₂ visualization. 468 However, we observed that the MDN can slip into the trocar due to the increased weight of 469 the device. Therefore, we have added a sterile rubber ring to the MDN that is pulled over the 470 nozzle and positioned so that it rests directly on the trocar head, while at the same time 471 achieving the ideal position for the MDN head. Finally, another important safety point is the
- achieving the ideal position for the MDN head. Finally, another important safety point is the consistent use of a single-arm holder, which additionally fixes the MDN in a strictly vertical position in the trocar. This measure also prevents the MDN from accidentally tilting sideways during the spraying process, which could affect the spatial distribution pattern of the drug. In
- order to better monitor this correct position intraoperatively, it would be desirable if the manufacturer could provide a safety mark indicating the ideal position of the MDN head in
- 477 the trocar. The manufacturer was informed of these points to improve the administrability and
- 478 safety of MDN-PIPAC.

463

- To further refine the intraoperative MDN-PIPAC safety checklist, based on our previous ex-
- 480 vivo simulations, we performed MDN-PIPAC in the large animal model immediately
- followed by CT-peritoneography to visualize the quality of the spatial aerosol distribution.
- The administration of all three MDN-PIPACs went without any technical or safety problems.
- 483 The CT-peritoneographies revealed wide aerosol deposition. In particular, areas such as the
- omental bursa, hepatic interlobar, and deep entero-enteric regions were also affected. Only the
- ventral parts of the abdominal cavity showed no contrast. However, large gravity-dependent
- fluid collections, as previously observed with a SDN, did not occur [27].
- 487 The clinical application of the elaborated intraoperative MDR-PIPAC safety checklist enabled
- 488 us to deliver 30 consecutive MDN-PIPACs without intraoperative problems. The
- 489 postoperative course was characterized by four patients with minor complications (Dindo-
- 490 Clavien grade I). Based on this initial experience, no clinical difference from SDN-PIPAC
- was observed at our institution [12].

5.0 CONCLUSION

492

- 494 Toxicological data show that the use of the MDN does not generate any leachable substances
- 495 that could pose a risk to patients. Ex-vivo simulations confirm the importance of correct
- 496 positioning of the MDN in the trocar and, if possible, in a periumbilical position. Schlieren
- 497 imaging during ex-vivo MDN-PIPAC simulations showed that even in a worst-case scenario,
- where the MDN head is incorrectly positioned in the trocar shaft, there is no backflow of CO₂
- 499 via the trocar valve into the environment. Consequently, no backflow of chemotherapy
- aerosol is assumed. Moreover, our first clinical data on the MDN-PIPAC shows that it is safe
- to use and causes no problems when the safety checklist is properly adapted to this device.
- 502 Finally, the perioperative clinical outcome of MDN-PIPAC is comparable to that of our
- patients previously treated with the SDN. Whether such new devices will have a positive

impact on clinical outcomes remains uncertain. Unfortunately, it is unlikely that there will be prospective studies in the near future to clarify this issue. Therefore, we suggest that the type of nebulizer used for PIPAC should also be documented in the ISSPP PIPAC database [35]. Such a large database could provide insight into the role of different nebulizers used in oncological outcomes.

REFERENCES

509

- 1. Di Giorgio A, Macrì A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino
- P, Sommariva A, Biacchi D, Roviello F, Pastorino R, Pires Marafon D, Rotolo S, Casella
- F, Vaira M. 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A
- 513 Systematic Review and Meta-Analysis. Cancers. 2023; 15(4):1125.
- 514 <u>https://doi.org/10.3390/cancers15041125</u>
- 515 2. Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich F-J, Königsrainer A, Reymond
- MA. Overcoming Drug Resistance by Taking Advantage of Physical Principles:
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers. 2020; 12(1):34.
- 518 <u>https://doi.org/10.3390/cancers12010034</u>
- 3. Göhler D, Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Falkenstein TA, Zieren J,
- Stintz M, Giger-Pabst U. Technical description of the microinjection pump (MIP®) and
- granulometric characterization of the aerosol applied for pressurized intraperitoneal
- 522 aerosol chemotherapy (PIPAC). Surg Endosc. 2017 Apr;31(4):1778-1784. doi:
- 523 10.1007/s00464-016-5174-5. Epub 2016 Sep 8. PMID: 27631320.
- 524 4. Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized
- 525 Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with
- Peritoneal Carcinomatosis: A Cohort Study. Anticancer Res. 2015 Dec;35(12):6723-9.
- doi: 10.1055/s-0035-1560004. PMID: 26637888.
- 528 5. Tavernier C, Passot G, Vassal O, Allaouchiche B, Decullier E, Bakrin N, Alyami M,
- Davigo A, Bonnet JM, Louzier V, Paquet C, Glehen O, Kepenekian V. Pressurized
- intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic
- leakage compared to HIPEC: an experimental study. Surg Endosc. 2020 Jul;34(7):2939-
- 532 2946. doi: 10.1007/s00464-019-07076-3. Epub 2019 Aug 27. PMID: 31456025.
- 6. Davigo A, Passot G, Vassal O, Bost M, Tavernier C, Decullier E, Bakrin N, Alyami M,
- Bonnet JM, Louzier V, Paquet C, Allaouchiche B, Glehen O, Kepenekian V. PIPAC
- 535 versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int J
- 536 Hyperthermia. 2020;37(1):144-150. doi: 10.1080/02656736.2019.1704891. PMID:
- 537 32003300.
- 538 7. Graversen M, Rouvelas I, Ainsworth AP, Bjarnesen AP, Detlefsen S, Ellebaek SB,
- 539 Fristrup CW, Liljefors MG, Lundell L, Nilsson M, Pfeiffer P, Tarpgaard LS, Tsekrekos A,
- Mortensen MB. Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination
- with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric
- Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study. Ann Surg Oncol. 2023 Mar
- 543 3. doi: 10.1245/s10434-023-13278-w. Epub ahead of print. PMID: 36867174.
- 8. Braet H, Andretto V, Mariën R, Yücesan B, van der Vegte S, Haegebaert R, Lollo G, De
- Smedt SC, Remaut K. The effect of electrostatic high pressure nebulization on the
- stability, activity and ex vivo distribution of ionic self-assembled nanomedicines. Acta
- 547 Biomater. 2023 Oct 15;170:318-329. doi: 10.1016/j.actbio.2023.08.027. Epub 2023 Aug
- 548 19. PMID: 37598790.

- 9. Göhler D, Oelschlägel K, Ouaissi M, Giger-Pabst U. Performance of different nebulizers
- in clinical use for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). medRxiv
- 551 2023.03.24.23287646; doi: https://doi.org/10.1101/2023.03.24.23287646

- 553 10. Kim G, Tan HL, Sundar R, Lieske B, Chee CE, Ho J, Shabbir A, Babak MV, Ang WH,
- Goh BC, Yong WP, Wang L, So JBY. PIPAC-OX: A Phase I Study of Oxaliplatin-Based
- Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
- Clin Cancer Res. 2021 Apr 1;27(7):1875-1881. doi: 10.1158/1078-0432.CCR-20-2152.
- 557 Epub 2020 Nov 4. PMID: 33148667.
- 11. Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, Abollino O,
- Ficiarà E, Cinquegrana A, Cavalli R, Vaira M. A Phase I Dose Escalation Study of
- Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal
- Carcinomatosis. Cancers (Basel). 2021 Mar 3;13(5):1060. doi: 10.3390/cancers13051060.
- 562 PMID: 33802269; PMCID: PMC7958944.
- 12. Ramos Arias G, Sindayigaya R, Ouaissi M, Buggisch JR, Schmeding M, Giger-Pabst U,
- Zieren J. Safety and Feasibility of High-Pressure/High-Dose Pressurized Intraperitoneal
- Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and Metastatic Peritoneal Surface
- Malignancies. Ann Surg Oncol. 2022 Nov 18. doi: 10.1245/s10434-022-12698-4. Epub
- ahead of print. PMID: 36400887.
- 13. Du Bois, D. and Du Bois, E.F. A Formula to Estimate the Approximate Surface Area if
- Height and Weight Be Known. Archives of Internal Medicine. 1916;17, 863-871.
- 570 http://dx.doi.org/10.1001/archinte.1916.00080130010002
- 571 14. ISO (International Standardisation Organisation). 2020. ISO 10993-18:2020. Biological
- evaluation of medical devices. Part 18: Chemical characterization of medical device
- 573 materials within a risk management process
- 574 15. ISO (International Standardisation Organisation). ISO 10993-17:2023. Biological
- evaluation of medical devices. Part 17: Toxicological risk assessment of medical device
- 576 constituents
- 577 16. Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized
- Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of
- 579 1200 Procedures. Journal of Gastrointestinal Surgery: Official Journal of the Society for
- Surgery of the Alimentary Tract. 2018 Dec;22(12):2187-2193.
- 581 17. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol
- chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013
- 583 Oct;20(11):3504-11. doi: 10.1245/s10434-013-3039-x. Epub 2013 Jun 14. PMID:
- 584 23765417; PMCID: PMC3764316.
- 585 18. Gena AW, Voelker C, Settles GS. Qualitative and quantitative schlieren optical
- 586 measurement of the human thermal plume. Indoor Air. 2020;30:757-766.
- 587 https://doi.org/10.1111/ina.12674
- 19. Alsaad H, Schälte G, Schneeweiß M, Becher L, Pollack M, Gena AW, Schweiker M,
- Hartmann M, Voelker C, Rossaint R, et al. The Spread of Exhaled Air and Aerosols
- 590 during Physical Exercise. Journal of Clinical Medicine. 2023; 12(4):1300.
- 591 https://doi.org/10.3390/jcm12041300
- 592 20. Dellweg D, Kerl J, Gena AW, Alsaad H, Voelker C. Exhalation Spreading During Nasal
- High-Flow Therapy at Different Flow Rates. Crit Care Med. 2021 Jul 1;49(7):e693-e700.
- doi: 10.1097/CCM.00000000000000009. PMID: 34135285; PMCID: PMC8204857.
- 595 21. Meyers MA. Peritoneography: Normal and Pathologic Anatomy. In: Dynamic Radiology
- of the Abdomen. Springer, New York, NY. 1976; ISBN: 978-1-4757-3957-2

- 597 22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new
- 598 proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg.
- 599 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PMID: 15273542; 600 PMCID: PMC1360123.
- 601 23. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de
- Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R,
- Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications:
- 604 five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2. PMID: 19638912.
- 24. Khosrawipour V, Khosrawipour T, Diaz-Carballo D, Förster E, Zieren J, Giger-Pabst U.
- Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol
- 608 Chemotherapy (PIPAC). Ann Surg Oncol. 2016 Apr;23(4):1220-4. doi: 10.1245/s10434-
- 609 015-4954-9. Epub 2015 Nov 9. PMID: 26553440.
- 25. Davigo A, Passot G, Vassal O, Bost M, Tavernier C, Decullier E, Bakrin N, Alyami M,
- Bonnet JM, Louzier V, Paquet C, Allaouchiche B, Glehen O, Kepenekian V. PIPAC
- versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int J
- Hyperthermia. 2020;37(1):144-150. doi: 10.1080/02656736.2019.1704891. PMID:
- 614 32003300.
- 26. Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S,
- Demtröder C, Salamé E, Ouaissi M. Comparison of Tissue and Blood Concentrations of
- Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann
- Surg Oncol. 2019 Dec;26(13):4445-4451. doi: 10.1245/s10434-019-07695-z. Epub 2019
- 619 Aug 9. PMID: 31399820.
- 620 27. Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigteroth S, Cohnen J, Diaz-Carballo
- D, Bockisch A, Zieren J, Giger-Pabst U. Scintigraphic peritoneography reveals a non-
- uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal
- Aerosol Chemotherapy (PIPAC) in a swine model. Surg Endosc. 2018 Jan;32(1):166-174.
- doi: 10.1007/s00464-017-5652-4. Epub 2017 Jun 22. PMID: 28643076.
- 625 28. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration:
- tissue penetration and surface exposure. J Natl Cancer Inst. 1997 Apr 2;89(7):480-7. doi:
- 627 10.1093/jnci/89.7.480. PMID: 9086004.
- 628 29. Khosrawipour V, Khosrawipour T, Falkenstein TA, Diaz-Carballo D, Förster E, Osma A,
- 629 Adamietz IA, Zieren J, Fakhrian K. Evaluating the Effect of Micropump[©] Position,
- 630 Internal Pressure and Doxorubicin Dosage on Efficacy of Pressurized Intra-peritoneal
- Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. Anticancer Res. 2016
- 632 Sep;36(9):4595-600. doi: 10.21873/anticanres.11008. PMID: 27630300.
- 633 30. Piao J, Park SJ, Lee H, Kim J, Park S, Lee N, Kim SI, Lee M, Song G, Lee JC, Kim HS;
- KORIA TRIAL GROUP. Ideal Nozzle Position During Pressurized Intraperitoneal
- Aerosol Chemotherapy in an Ex Vivo Model. Anticancer Res. 2021 Nov;41(11):5489-
- 636 5498. doi: 10.21873/anticanres.15362. PMID: 34732419.
- 637 31. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a
- 638 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
- 639 PMID: 33842275; PMCID: PMC8033043.

- 32. Park SJ, Lee EJ, Lee HS, Kim J, Park S, Ham J, Mun J, Paik H, Lim H, Seol A, Yim GW,
- Shim SH, Kang BC, Chang SJ, Lim W, Song G, Kim JW, Lee N, Park JW, Lee JC, Kim
- HS; KoRIA* trial group. Development of rotational intraperitoneal pressurized aerosol
- chemotherapy to enhance drug delivery into the peritoneum. Drug Deliv. 2021
- Dec;28(1):1179-1187. doi: 10.1080/10717544.2021.1937382. PMID: 34121568; PMCID:
- 645 PMC8204987.
- 33. Braet H, Andretto V, Mariën R, Yücesan B, van der Vegte S, Haegebaert R, Lollo G, De
- Smedt SC, Remaut K. The effect of electrostatic high-pressure nebulization on the
- stability, activity and ex vivo distribution of ionic self-assembled nanomedicines. Acta
- Biomater. 2023 Aug 19:S1742-7061(23)00492-0. doi: 10.1016/j.actbio.2023.08.027. Epub
- ahead of print. PMID: 37598790.
- 34. Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol
- Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal
- metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018 Jun
- 654 21;3(2):20180116. doi: 10.1515/pp-2018-0116. PMID: 30911659; PMCID:
- 655 PMC6405009.
- 35. Mortensen MB, Glehen O, Horvath P, Hübner M, Hyung-Ho K, Königsrainer A, Pocard
- M, Reymond MA, So J, Fristrup CW. The ISSPP PIPAC database: design, process,
- access, and first interim analysis. Pleura Peritoneum. 2021 Apr 22;6(3):91-97. doi:
- 659 10.1515/pp-2021-0108. PMID: 34676282; PMCID: PMC8482445.

Figures and Tables

Table 1: Toxicological analyses after nebulization of chemotherapy with the MDN

Methods of Analysis	Doxorubicin + Cisplatin	Oxaliplatin	
HSGC-MS analysis for Volatile Organic Compounds	Not detected	Not detected	
GC-MS analysis for Semi-Volatile Organic Compounds			
1, 6, 11, 16-Tetraoxacycloeicosane1, 6, 11, 16, 21-Pentaoxacyclopentacosane	Not detected Not detected	0.03 μg/ml 0.04 μg/ml	
LC-MS analysis for Non-Volatile Organic Compounds			
 Cyclic polybutylene glycol (C20) Cyclic polybutylene glycol (C24) Cyclic polybutylene glycol (C32) 	$\begin{array}{c} 0.144~\mu\text{g/ml} \\ 0.246~\mu\text{g/ml} \\ 0.083~\mu\text{g/ml} \end{array}$	0.131 µg/ml 0.123 µg/ml 0.045 µg/ml	
ICP-MS analysis for inorganic elements		-	
CupperFerrumManganese	$0.049 \ \mu g/ml \ 0.057 \ \mu g/ml \ 0.015 \ \mu g/ml$	Not detected 0.011 µg/ml 0.014 µg/ml	
IC analysis for anions			
 Acetates Fluorides Chlorides Bromides Nitrites Nitrates Sulfates 	Not detected Not detected Not detected Not detected Not detected Not detected	Not detected Not detected Not detected Not detected Not detected Not detected	
- Phosphates	Not detected	Not detected	

Legend: HSGC-MS = Head-space Gas Chromatography coupled with Mass Spectrometry; GC-MS = Gas Chromatography coupled with Mass Spectrometry; LC-MS = Liquid phase chromatography coupled to a Mass Spectrometer; ICP-OES = Inductively Coupled Plasma Atomic Emission Spectrometry; IC = Ion Chromatography;

Variables	Total population		
	(n = 21)		
Age at first MDN-PIPAC (mean (range) in years)	62 (38-86)		
Primary origin (n)			
- Colo-Rectal	3		
- UGI	6		
- НРВ	3		
- MPM	2		
- Ovarian	4		
- Other	3		
ECOG (n)			
- 0 1	5 16		
Synchronous PSM (n)	10		
Prior primary tumor resection (n)	17		
Prior systemic chemotherapy lines (median (range))	2 (1-5)		
Prior standard PIPAC applications before MDP-PIPAC (median (range))	1 (1-4)		
Ongoing systemic chemotherapy between MDN-PIPAC procedures (n)	14		
The time between primary and metachronous PSM diagnosis (mean			
(range) in months)	21 (2-56)		

 Table 2: Baseline clinical characteristics of the patients with MDN-PIPAC

674

Legend: PIPAC = pressurized intraperitoneal aerosol chemotherapy; MDN = multidirectional nebulizer; UGI = upper gastrointestinal; HPB = hepato- biliary tract; ECOG = Eastern Cooperative Oncology Group performance status; PSM = peritoneal surface malignancy

Figure 1: The schlieren imaging system at the Bauhaus-University Weimar

675




Figure 2: Test setup for schlieren imaging during ex-vivo MDN-PIPAC simulations

678

680





Figure 3: Ex-vivo evaluation of the optimal position of the MDN in the 12-mm trocar




Legend: A = MDN inserted into a 12 mm balloon trocar. The position of the MDN head must be checked visually so that the lateral nozzles do not nebulize into the trocar. The white triangles mark the distal end of the trocar. Note that the trocar is angled 15° at the distal end. The black arrows point to the horizontal nozzle openings. These should protrude at least 7 mm beyond the most distal end of the trocar (left white arrow). B = MDN inserted into a 12 mm balloon trocar. The black arrow points to the sterile rubber ring pulled over the nebulizer shaft which rests on the trocar head to prevent the nebulizer from gliding into the trocar.

Figure 4: Periumbilical position of the MDN for optimized nebulization

692

693

694 695



Legend: A = Sketch of infraumbilical position of the MDN for optimized nebulization of all four nozzles (only horizontal nozzles shown); B = intraoperative view on the MDN head


Figure 5: Schlieren imaging of different scenarios of MDN-PIPAC simulation

697

698


699

700



Legend: A = a test schlieren image to demonstrate the visualization of CO_2 leakage; B = schlieren visualization of 12 mmHg injection at 1.3 ml/s with a 50 ml of distilled water

Figure 6: Representative MDN-PIPAC CT-peritoneography images of pig N° 1



Legend: A1-C1 = horizontal section planes; A2-C2 = coronal section planes. The white triangles point to the contrast agent accumulation: A1-C1 = enter-enteric and paracolic left; A2 = subdiaphragmatic bilateral; B2 = homogeneous on the Glisson capsule, subhepatic and interlobar; C2 = perigastric and perilienal